

AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/038
Drug name and formulations:		Epiduo® gel (adapalene 0.1% & benzoyl peroxide 2.5%)
Criteria	Example	Committee Consensus
Patient Safety	<i>Potential for abuse, toxicity, significant drug interactions</i>	Associated with some adverse effects such as skin irritation which can be relieved by over the counter moisturisers. Does not contain antimicrobial agent so may reduce risk of resistance.
Clinical effectiveness	<i>Established licensed product</i>	Established licensed product. Efficacy is equivalent to Duac® Once Daily.
Strength of evidence		Good, RCTs comparing to placebo and comparator.
Cost effectiveness or resource impact	£	Cost neutral compared to comparator.
Place of therapy relative to available treatments	<i>1/2nd tier</i>	1 st line; may be used in preference to antimicrobial-containing agents.
National guidance and priorities	<i>NICE, MTRAC</i>	NICE CKS, PCDS guidelines support use.
Local health priorities	<i>CCG views</i>	CCGs support use, especially in view of antimicrobial stewardship.
Equity of access	<i>Equality assessment</i>	N/A
Stakeholder views	<i>Define wider groups to be engaged</i>	N/A
Implementation requirements	<i>Requires, RICAD ESCA etc.</i>	None

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN <u>Rationale</u> : offers an additional treatment choice and may be used in preference to antimicrobial containing agents to reduce use of topical antibiotics.
Implementation requirements:	
Implementation monitoring:	

